Michinori Kohara

This inventor holds 19 USPTO granted patents and 11 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in Viral Inhibition Research. Top assignees: Tokyo Metropolitan Institute of Medical Science, Chugai Seiyaku Kabushiki Kaisha, Phoenixbio Co., Ltd.. Active years: 2001-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michinori Kohara. Retrieved from https://idiyas.com/inventor/michinori-kohara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 11)

% Patents Active = 84.2

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 15)

Average Co-Inventor Count = 3.8

ph-index = 1

Forward Citations = 2(Granted Patents)

Location History:

Chiba, JP (2001 - 2003)
Tokyo, JP (2013 - 2022)

Company Filing History:

14 out of 56

Tokyo Metropolitan Institute of Medical Science

patents

4 out of 987

Chugai Seiyaku Kabushiki Kaisha

Chemo-Sero-Therapeutic Research Institute

Prism Pharma Co., Ltd.

Km Biologics Co., Ltd.

National Institute of Infectious Diseases

patents

13. 1 out of 23

National Institutes of Biomedical Innovation, Health and Nutrition

Tokyo Yakuhin Kogyo Co., Ltd.

patent

16. 2 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2025

Loading Chart...

Areas of Expertise:

Hepatitis B Virus

Dengue Vaccine

Electroporation

Hepatic Fibrosis

Hepatitis C Virus

Transgenic Mouse

Viral Inhibitors

Pharmaceutical Composition

RNA Polymerase

Peptide Nucleic Acid

Vaccine Composition

Animal Model

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12458658 - Composition for inhibiting replication of hepatitis B virus (2025-11-04),

2. 12280099 - Dengue virus vaccine (2025-04-21),

3. 11517741 - Electrodes for electroporation (2022-12-06),

4. 11491219 - Nasal hepatitis B vaccine composition and method for producing same (2022-11-08),

5. 11051496 - Urokinase-type plasminogen activator transgenic mouse (2021-07-06),

6. 10632187 - Hemagglutinin-binding peptide (2020-04-28),

7. 10328143 - Hemagglutinin-binding peptide (2019-06-25),

8. 10265331 - Prevention or treatment agent for hepatic fibrosis (2019-04-23),

9. 10160979 - Pharmaceutical composition for treatment and/or prevention of hepatitis C (2018-12-25),

10. 9955675 - Urokinase-type plasminogen activator transgenic mouse (2018-05-01),

11. 9700569 - Prevention or treatment agent for hepatic fibrosis (2017-07-11),

12. 9000136 - Recombinant vaccinia virus having hepatitis C virus gene (2015-04-07),

13. 8957199 - Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis C virus (2015-02-17),

14. 8609403 - Polynucleotide derived from novel hepatitis C virus strain and use thereof (2013-12-17),

15. 8466273 - Hepatitis C virus inhibitors (2013-06-18),

Title: Michinori Kohara: Pioneering Innovations in Medical Science

Introduction

Michinori Kohara, based in Tokyo, Japan, is a prominent inventor with an impressive portfolio of 18 patents. His work primarily focuses on advancements in medical science, particularly vaccines and electroporation technology. Kohara's innovative spirit has led to significant contributions that aim to improve public health.

Latest Patents

Among his latest patents is a groundbreaking dengue virus vaccine. This invention involves a recombinant Vaccinia virus designed as both a therapeutic and prophylactic agent, showcasing the inclusion of a non-structural protein from the dengue virus along with an expression promoter. Another notable patent is for electrodes used in electroporation. This device features multiple electrode needles and is designed for effective insertion and removal of syringe needles, thereby enhancing the electroporation target procedure.

Career Highlights

Throughout his career, Michinori Kohara has worked with respected institutions such as the Tokyo Metropolitan Institute of Medical Science and Chugai Pharmaceutical Co., Ltd. His tenure at these organizations has enabled him to collaborate with leading professionals in the medical field, pushing the boundaries of research and innovation.

Collaborations

Kohara has collaborated with talented individuals such as Kyoko Kohara and Chise Mukaidani. Their teamwork illustrates the importance of collaboration in driving innovative solutions within medical research and technology.

Conclusion

Michinori Kohara continues to make significant strides in the realm of medical innovations. His extensive research and patented inventions reflect a commitment to improving healthcare and combating infectious diseases. As he advances his work, the impact of his contributions will undoubtedly resonate within the scientific community and beyond.

Profile summary based on public USPTO records.